James M. Isbell, MD, MSCI
Thoracic Surgeon
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Lung Cancer
- Minimally Invasive Surgery, Robotic Surgery
- Video-Assisted Thoracic Surgery (VATS)
About Me
- Director, Quality and Outcomes, Thoracic Surgery Service, Director, Memorial Hospital Step Down Unit, Co-Director, Thoracic Liquid Biopsy Program
I am a thoracic surgeon who cares for people with cancers of the chest. These include lung cancer, esophageal cancer, mediastinal tumors, thymic tumors, mesothelioma and chest wall tumors, as well as cancers that have metastasized (spread) to the lung from other parts of the body.
Read more
I have particular expertise in minimally invasive techniques such as robotic-assisted and video-assisted thoracic surgery, which can help minimize pain and speed recovery. I see approximately 400 patients with cancers of the chest each year and perform approximately 300 procedures annually. I strive to use minimally invasive approaches whenever possible so patients can recover as quickly as possible.
Having experienced cancer in several members of my own family, I can relate to how patients and their families may feel overwhelmed by a new cancer diagnosis and the potential treatment options. It can be intimidating to select which treatment is right for them. I take the time to answer patients’ questions so they have all the information they need to decide the next steps in their care. I work closely with my colleagues in medical oncology, radiation oncology, and pathology to develop a treatment plan for each patient that reflects their wishes for the best possible outcome and an improved quality of life.
In addition to being a thoracic surgeon, I am board-certified in surgical critical care and take care of patients in MSK’s Intensive Care Unit (ICU). I also serve as Director of the Memorial Hospital Step-Down Unit, which provides care for medical and surgical patients who need intermediate-level care.
As Co-Director of MSK’s multidisciplinary Thoracic Liquid Biopsy Program, I research liquid biopsies - technologies that test blood and other fluids and are therefore less invasive than tissue biopsies. Liquid biopsies can improve the early detection and precision treatment of lung cancer, as well as monitor changes in a patient’s disease. I am leading clinical trials to investigate whether a liquid biopsy is useful in guiding treatment decisions among patients with early lung cancers that can be surgically removed, and to test for the very first signs that their cancer has recurred when there is a better chance of curative treatment.
I also study ways to better predict complications after surgery to help patients with thoracic cancers decide which treatment is best for them.
Outside of work I enjoy spending time with my wife, who is a pediatrician, and our three children. We have fun going hiking and camping and often take weekend road trips. We also love traveling. Our most memorable trip was to Ireland, and we look forward to planning our next vacation together.
A thoracic (thor-A-sik) surgeon is a doctor with special training in surgery on the chest, lungs, trachea (windpipe), and thymus.
My Specialties
- Lung Cancer
- Minimally Invasive Surgery, Robotic Surgery
- Video-Assisted Thoracic Surgery (VATS)
- Esophageal Cancer
- Esophageal Disorders
- Mediastinal Tumors
- Thymic Tumors
- Chest Wall Tumors
- Pulmonary Metastases
- Mesothelioma
- Endobronchial Ultrasound (EBUS)
- Pleural Diseases
- Liquid Biopsy
Education
- MD, University of Texas Southwestern Medical School
Residencies
- General Surgery - Vanderbilt University Medical Center
- Thoracic Surgery - University of Virginia Health System
Awards and Honors
- Castle Connolly: America’s Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
Fellowships
- Surgical Critical Care - University of Virginia Health System
- Surgical Critical Care - Johns Hopkins School of Medicine
Board Certifications
- General Surgery
- Thoracic Surgery
- Surgical Critical Care
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Isbell sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Isbell JM, Deppen S., Putnam J.B. Jr., Nesbitt J.C., Lambright E.S., Dawes A., MassionP.P., Speroff T., Jones D.R., and Grogan E.L. Existing general population models inaccurately predict lung cancer risk in patients referred for surgical evaluation. Annals of Thoracic Surgery 91:227-33, 2011.
Isbell JM and Jones DR. Parenchymal-sparing lung resections: technique of sleeve resections. Operative Techniques in Thoracic and Cardiovascular Surgery: A Comparative Atlas. 2011; 16:215-25.
Taylor MD, Lapar DJ, Davis JP, Isbell JM, Kozower BD, Lau CL, Jones DR. Induction chemoradiotherapy and surgery for esophageal cancer: survival benefit with downstaging. Annals of Thoracic Surgery 96: 225-230, 2013.
Read more
Walters DM, Vaughn NH, Isbell JM, Jeffus SK, Atkins KA, Sauer BG, Jones DR. Leiomyoma presenting as a massive calcified circumferential esophageal mass. Annals of Thoracic Surgery. 2013; 96:1851-4.
Taylor MD, Lapar DJ, Isbell JM, Kozower BD, Lau CL, Jones DR. Marginal pulmonary function should not preclude lobectomy in selected patients with non-small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery. 2014; 147:738-44.
Hu Y, McMurry TL, Wells KM, Isbell JM, Stukenborg GJ, Kozower BD. Postoperative mortality is an inadequate quality indicator for lung cancer resection. Annals of Thoracic Surgery. 2014; 97:973-9.
Hu Y, McMurry TL, Isbell JM, Stukenborg GJ, Kozower BD. Readmission after lung cancer resection is associated with a 6-fold increase in 90-day postoperative mortality. Journal of Thoracic and Cardiovascular Surgery. 2014; 148:2261-7.
Walters DM, McMurry TL, Isbell JM, Stukenborg GJ, Kozower BD. Understanding mortality as a quality indicator after esophagectomy. Annals of Thoracic Surgery. 2014; 2:506-512.
Kiankhooy A, Taylor MD, LaPar DJ, Isbell JM, Lau CL, Kozower BD, Jones DR. Predictors of early recurrence for node-negative T1 and T2 non-small cell lung cancer. Annals of Thoracic Surgery. 2014; 4:1175-83.
Visit PubMed for a full listing of Dr. Isbell’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
James M. Isbell discloses the following relationships and financial interests:
-
AstraZeneca
Professional Services and Activities -
Intuitive Surgical Inc.
Professional Services and Activities
-
LumaCyte
Equity -
Merck Sharp & Dohme
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].